270 related articles for article (PubMed ID: 26758620)
1. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
Li J; Chen JN; Zeng TT; He F; Chen SP; Ma S; Bi J; Zhu XF; Guan XY
BMC Cancer; 2016 Jan; 16():15. PubMed ID: 26758620
[TBL] [Abstract][Full Text] [Related]
2. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
3. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
4. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.
Liu YM; Li XF; Liu H; Wu XL
Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
7. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
8. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
Jia Q; Zhang X; Deng T; Gao J
Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
[TBL] [Abstract][Full Text] [Related]
10. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
[TBL] [Abstract][Full Text] [Related]
11. Latexin inhibits the proliferation of CD133+ miapaca-2 pancreatic cancer stem-like cells.
Xue ZX; Zheng JH; Zheng ZQ; Cai JL; Ye XH; Wang C; Sun WJ; Zhou X; Lu MD; Li PH; Cai ZZ
World J Surg Oncol; 2014 Dec; 12():404. PubMed ID: 25551472
[TBL] [Abstract][Full Text] [Related]
12. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo.
Jin Y; Mao J; Wang H; Hou Z; Ma W; Zhang J; Wang B; Huang Y; Zang S; Tang J; Li L
Biomed Pharmacother; 2013 May; 67(4):337-45. PubMed ID: 23582787
[TBL] [Abstract][Full Text] [Related]
13. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
[TBL] [Abstract][Full Text] [Related]
15. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma.
Tong M; Fung TM; Luk ST; Ng KY; Lee TK; Lin CH; Yam JW; Chan KW; Ng F; Zheng BJ; Yuan YF; Xie D; Lo CM; Man K; Guan XY; Ma S
Stem Cell Reports; 2015 Jul; 5(1):45-59. PubMed ID: 26095609
[TBL] [Abstract][Full Text] [Related]
16. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
[TBL] [Abstract][Full Text] [Related]
17. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.
Piao LS; Hur W; Kim TK; Hong SW; Kim SW; Choi JE; Sung PS; Song MJ; Lee BC; Hwang D; Yoon SK
Cancer Lett; 2012 Feb; 315(2):129-37. PubMed ID: 22079466
[TBL] [Abstract][Full Text] [Related]
18. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
19. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
20. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
